Recent FDA approvals (through May 2009) related to Coartem, Ixiaro, Lexapro, Reclast, and Symbyax
Artemether 20 mg/lumefantrine 120 mg (Coartem, Novartis) was approved for the treatment of acute uncomplicated infections due to Plasmodium falciparum.
A vaccine (Ixiaro, Intercell) was approved for active immunization against viral infections of Japanese encephalitis.
Escitalopram (Lexapro, Forest) was approved for the acute and maintenance treatment of major depressive disorder in adolescent patients aged 12 to 17 years.
The combination of olanzapine and fluoxetine (Symbyax, Lilly) was approved for the acute treatment of treatment-resistant depression. Olanzapine (Zyprexa, Lilly) and fluoxetine (Prozac, Lilly) were also approved for use in combination for the acute treatment of treatment-resistant depression and for the acute treatment of bipolar depression.
Benzyl alcohol lotion, 5% concentration (Sciele) was approved for the treatment of head lice infestation in patients aged ≥6 months.
Skyrizi Overtakes Humira in U.S. Sales Numbers
November 8th 2024For the first time, Skyrizi has replaced Humira as AbbVie’s sales driver, largely due to companies encouraging “product hopping” to avoid competition, creating concerns for the sustainability of the burgeoning adalimumab biosimilar market.
Read More
FDA Advisory Committee Votes Down Sotagliflozin in Type 1 Diabetes and CKD
November 1st 2024Committee members said there was uncertainty around sotagliflozin in patients with kidney disease. The FDA is currently reviewing the oral therapy as an adjunct to insulin to help control glycemic levels in adults with type 1 diabetes and chronic kidney disease. The agency’s goal date is Dec. 20, 2024.
Read More